June 13, 2022

Amvuttra™ (vutrisiran) has been approved to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

  • A rapidly progressing disease with a poor prognosis, hATTR causes abnormal proteins to accumulate in the body’s tissues. This can lead to neuropathy, which occurs when damage or dysfunction of the nerves leads to numbness, tingling, weakness, and pain.
  • Recommended dosing for Amvuttra is 25mg administered via subcutaneous injection by a healthcare professional once every three months.
  • Manufacturer Alnylam Pharmaceuticals has launched Amvuttra at a wholesale acquisition cost (WAC) of $115,875 per syringe.
July 31, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in August

Read More
July 19, 2022

FDA Approves First Therapy for Repigmentation in Vitiligo

Read More
July 15, 2022

Zonisade Approved to Treat Seizures

Read More
July 14, 2022

Xalkori Granted New Indication to Treat Non-Cancerous Tumors

Read More